FY2025 Earnings Forecast for Ocugen Issued By HC Wainwright

Key Points

• HC Wainwright has increased its FY2025 earnings per share (EPS) estimate for Ocugen to ($0.20), up from ($0.21), while maintaining a "Buy" rating and a $7.00 target price.
• For the most recent quarter, Ocugen reported earnings of ($0.05) per share, exceeding analyst expectations of ($0.06), with revenue of $1.37 million against analyst estimates of $0.35 million.
• Several institutional investors have increased their stakes in Ocugen, with Vanguard Personalized Indexing Management boosting its position by 48.8% during the second quarter.

Ocugen, Inc. (NASDAQ:OCGN - Free Report) - Equities researchers at HC Wainwright boosted their FY2025 EPS estimates for shares of Ocugen in a report issued on Monday, August 4th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.20) per share for the year, up from their prior estimate of ($0.21). HC Wainwright has a "Buy" rating and a $7.00 price objective on the stock. The consensus estimate for Ocugen's current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Ocugen's FY2027 earnings at ($0.08) EPS, FY2028 earnings at $0.24 EPS and FY2029 earnings at $1.13 EPS.

Ocugen (NASDAQ:OCGN - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. The business had revenue of $1.37 million for the quarter, compared to analyst estimates of $0.35 million. Ocugen had a negative net margin of 1,197.71% and a negative return on equity of 255.25%.

Separately, Chardan Capital reiterated a "buy" rating and set a $7.00 price target on shares of Ocugen in a research report on Monday, August 4th.

Ocugen Stock Performance

OCGN stock traded down $0.01 during midday trading on Thursday, hitting $0.99. 1,880,726 shares of the stock traded hands, compared to its average volume of 4,615,454. The stock's fifty day simple moving average is $1.04 and its 200-day simple moving average is $0.81. The company has a debt-to-equity ratio of 9.18, a current ratio of 1.83 and a quick ratio of 1.83. The firm has a market cap of $287.92 million, a P/E ratio of -4.93 and a beta of 3.84. Ocugen has a 1-year low of $0.52 and a 1-year high of $1.40.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. boosted its holdings in shares of Ocugen by 149.2% during the fourth quarter. JPMorgan Chase & Co. now owns 296,615 shares of the company's stock valued at $239,000 after acquiring an additional 177,594 shares during the period. Wellington Management Group LLP lifted its holdings in Ocugen by 10.5% in the fourth quarter. Wellington Management Group LLP now owns 507,495 shares of the company's stock worth $409,000 after purchasing an additional 48,393 shares during the period. Geode Capital Management LLC grew its stake in Ocugen by 4.9% during the 4th quarter. Geode Capital Management LLC now owns 6,588,407 shares of the company's stock valued at $5,305,000 after acquiring an additional 309,853 shares in the last quarter. Wells Fargo & Company MN grew its stake in shares of Ocugen by 63.3% in the 4th quarter. Wells Fargo & Company MN now owns 141,773 shares of the company's stock valued at $114,000 after buying an additional 54,935 shares in the last quarter. Finally, Invesco Ltd. boosted its position in Ocugen by 39.0% during the fourth quarter. Invesco Ltd. now owns 173,553 shares of the company's stock worth $140,000 after purchasing an additional 48,679 shares during the period. Hedge funds and other institutional investors own 10.27% of the company's stock.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.